BioCorteX in practice - Carbon Mirror de-risks drug development

BioCorteX takes a unique approach to therapeutics by considering three specific interactions between bacteria: the direct effect of drug-bacteria metabolism, the indirect effect of bacteria and the host physiology, and the local effects on specific tissues, like the tumour microbiome.

Pharmaceuticals

In modern drug development, the makeup of an individual’s bacteria is a complex and expensive problem. The possible bacterial permutations that need to be analysed are almost infinite and performing the necessary analysis takes exceptional computational and financial resources.

As a result, the magnitude of diversity in the human microbiome is overlooked, leading to costly clinical trial failures and the continued use of medicines with varying levels of response.

At BioCorteX our foundational emulator has the ability to conduct advanced computational scenarios that model complex human responses. This provides the BioCorteX team and partners with the opportunity to test drug-bacteria interactions time and time again, in silico.

We have conducted in silico trials of hundreds of medications and assets in development to understand the factors that determine success. 

By providing actionable insights at any stage of drug development BioCorteX can de-risk clinical trials, increase chances of trial success and improve internal rates of return, while providing better outcomes for people worldwide.